Jabber update for all School of Medicine Staff

-

SOM is transitioning the university’s softphone service from Cisco Jabber to Cisco Webex. The new
platform is called Cardinal Voice Softphone and expands on the Jabber features you rely on. Starting
now, Stanford University users can transition from Jabber to Webex by following the instructions below.

To avoid any interruption in your softphone service, install and configure Webex prior to Dec. 16, 2022.

What do I need to do?
Don’t worry — it is a simple process and support is available if you need it. During the transition period,
Webex users can chat with Jabber users and vice versa, so there is no need to wait to get started with
the new Webex platform.

  1. To install Webex, go to Cardinal Voice Softphone Guide.
  2. Click the Webex download page button.
  3. Follow the steps to download Webex.

Why are Stanford’s softphone services changing?
Cisco, the vendor that provides both Jabber and Webex, is incorporating its Jabber features into Webex.
While the softphone and chat features work similarly, we want to take advantage of the enhancements
available with Webex, including:
• creating “spaces” where groups and teams can easily chat collaboratively
• sharing high-quality files
• sharing real-time video and audio
• using a more modern, intuitive interface

Where can I get more information?
Refer to the Cardinal Voice Softphone Guide for information about the new Webex platform, feature
instructions, and answers to Frequently Asked Questions.


If you need additional assistance, contact University IT at (650) 725-4357or submit a Help request.

DSMC Monitoring Update for Stanford Cancer Institute IITs

-

For studies that require DSMC monitoring and involve administration of investigational products (IP): 

Starting November 1, 2022, signed drug orders for oral IP will be requested as part of the study monitoring. 

Starting January 1, 2023, signed drug orders for any IP, regardless of type (oral, topical, intravenous, radiopharmaceutical, other), will be requested as part of the study monitoring. 

Of note, if your study utilizes Beacon for investigational drug orders, please indicate that in the monitoring questionnaire. In which case, you do not need to provide the drug orders, if you are able to confirm that the drug orders are available in Beacon. 

We ask that all drug orders are provided for the patients selected for monitoring. This change will be reflected in the monitoring requests that are sent out. If you have any questions or concerns, please reach out to our quality monitors at dsmc-quality@stanford.edu

SCI presenting 14th Comprehensive Cancer Research Training Program!

-

The Stanford Cancer Institute (SCI) will host the 14th Comprehensive Cancer Research Training Program (CCRTP) September 8-10, 2022, at the Lane History Corner. This immersive course provides a unique and comprehensive introduction to the vanguard of current cancer research.

Lectures will cover topics in:

• Pancreatic Cancer

• Drug Discovery & Development

• Cancer Disparities & Population Sciences

• How To Talks

This event is an excellent opportunity for attendees to connect and network. Learn more and register here:  http://med.stanford.edu/cancer/training/ccrtp.html

For questions and information, please contact Sanavy Lou, CCRTP Course Coordinator, at sanavy@stanford.edu.

Congrats Debjani!

-

Please join the Early Drug Development in congratulating Debjani Ghoshal, CRC2, who just graduated with a Master in Public Health (MPH) at the University of San Francisco. Debjani successfully juggled a full-time job while pursuing an advanced degree. We celebrate her great achievement!